Published in Biotech Law Weekly, March 24th, 2006
Arachnova acquired a license to data relating to this compound from Mitsubishi Pharma Corp. in February 2004 and has patented new therapeutic uses for the compound.
The data include toxicological and other non-clinical information, which underpinned a substantial clinical program involving over 350 patients. The novel uses identified by Arachnova are therapeutic switch developments in a variety of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.